Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05098613 Recruiting - Clinical trials for Non-Hodgkin Lymphoma

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). Phase 1 will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design. Phase 1b is an expansion phase designed to evaluate the preliminary efficacy of CD19x22 CAR T in CAR-treated and CAR-naïve patients.

NCT ID: NCT05097443 Recruiting - Clinical trials for Mantle Cell Lymphoma

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Start date: April 15, 2021
Phase: Phase 3
Study type: Interventional

B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL patients, there are still nearly one-third of patients who are resistant to initial treatment or relapse after remission. R-CHOP combined with novel drugs was expected to improve the prognosis. Therefore, this study aimed to investigate the potential of Orelabrutinib combined with Rituximab and chemotherapy.

NCT ID: NCT05096234 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Start date: September 28, 2021
Phase: Phase 2
Study type: Interventional

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

NCT ID: NCT05083936 Recruiting - Clinical trials for Patients With Suspected or Diagnosed Central Nervous System Lymphoma

Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma

Start date: August 27, 2021
Phase: N/A
Study type: Interventional

The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.

NCT ID: NCT05083208 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Start date: February 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.

NCT ID: NCT05081479 Recruiting - Lymphoma Clinical Trials

A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma

Start date: December 8, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

NCT ID: NCT05080166 Recruiting - Lymphoma Clinical Trials

UPLYFT For Lymphoma Survivors

Start date: February 8, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

NCT ID: NCT05079282 Recruiting - Clinical trials for Relapsed or Refractory T Cell Lymphoma

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Start date: December 10, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

NCT ID: NCT05078840 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin's, Adult

PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors

Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.

NCT ID: NCT05076097 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.